SAN DIEGO, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, announced today the company plans to participate in the 27th Annual Piper Jaffray Healthcare Conference in New York, NY. Neothetics management is scheduled for a fireside chat on Wednesday, December 2, 2015 at 2:00 p.m. ET.
About Neothetics, Inc.
Neothetics is a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market. The lead product candidate, LIPO-202, is for central abdominal bulging due to subcutaneous fat in non-obese subjects, an indication for which there is no FDA-approved drug. If approved, LIPO-202 may be a best-in-class non-surgical, non-ablative procedure and first-in-class injectable formulation for localized fat reduction and body contouring. For more information on Neothetics, please visit www.neothetics.com. Neothetics, LIPO-202, LIPO-102 and the Neothetics logo are trademarks or registered trademarks of Neothetics, Inc. Other names and brands may be claimed as the property of others.
CONTACT: Susan A. Knudson Chief Financial Officer 858-500-7780 firstname.lastname@example.org Fara Berkowitz, R.Ph, Pharm.D Senior Director, Investor Relations and Corporate Strategy 917-460-9307 email@example.com